Illumina (ILMN) Lands Singapore Genome Project Covering 450,000 Residents

Simply Wall St.05:22

Illumina (NasdaqGS: ILMN) has been selected for Phase III of Singapore's National Precision Medicine Programme, as announced for the SG-INSIGHT study. The company will provide whole-genome sequencing ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2680705596?lang=en_US&edition=fundamental","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/9551728-choice1-card/1788934355557","is_english":true,"pubTime":"2026-11-04 05:22","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2680705596","market":"us","top_or_hot":-1,"title":"Illumina (ILMN) Lands Singapore Genome Project Covering 450,000 Residents","media":"Simply Wall St.","content":"<div>\n<p>Illumina (NasdaqGS: ILMN) has been selected for Phase III of Singapore's National Precision Medicine Programme, as announced for the SG-INSIGHT study. The company will provide whole-genome sequencing ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ilmn/illumina/news/illumina-ilmn-lands-singapore-genome-project-covering-450000\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Illumina (ILMN) Lands Singapore Genome Project Covering 450,000 Residents</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIllumina (ILMN) Lands Singapore Genome Project Covering 450,000 Residents\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-11-04 05:22 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ilmn/illumina/news/illumina-ilmn-lands-singapore-genome-project-covering-450000><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Illumina (NasdaqGS: ILMN) has been selected for Phase III of Singapore's National Precision Medicine Programme, as announced for the SG-INSIGHT study. The company will provide whole-genome sequencing ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ilmn/illumina/news/illumina-ilmn-lands-singapore-genome-project-covering-450000\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4535","symbol_name":"淡马锡持仓","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ilmn/illumina/news/illumina-ilmn-lands-singapore-genome-project-covering-450000","article_id":"2680705596","we_media_id":null,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/9551728-choice1-card/1788934355557"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ilmn/illumina/news/illumina-ilmn-lands-singapore-genome-project-covering-450000","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2680705596","pubTimestamp":1793740960,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Illumina (NasdaqGS: ILMN) has been selected for Phase III of Singapore's National Precision Medicine Programme, as announced for the SG-INSIGHT study.\nThe company will provide whole-genome sequencing for approximately 450,000 residents, supporting large scale population genomics in Singapore.\nThis engagement builds on earlier collaborations in the country and extends Illumina's operational and regulatory footprint across Asia.\nIllumina's role in the SG-INSIGHT whole-genome project is...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4535":"淡马锡持仓","ARTY":"ISHARES FUTURE AI & TECH ETF","BK4548":"巴美列捷福持仓","AIPO":"Defiance AI and Power Infrastructure ETF","CHAT":"ROUNDHILL GENERATIVE AI & TECHNOLOGY ETF","BK4588":"碎股","VTHR":"Vanguard Russell 3000 ETF","BK4121":"生命科学工具和服务","ILMN":"Illumina","AGIX":"通用人工智能 ETF-AGIX","LU0128526141.USD":"TEMPLETON GLOBAL SMALLER COMPANIES \"A\" ACC","BMED":"iShares Health Innovation Active ETF","LU0029874061.USD":"TEMPLETON GLOBAL SMALLER COMPANIES \"A\" YDIS INC","QTOC":"Innovator Growth Accelerated Plus ETF - October","BK4585":"ETF&股票定投概念","BK4534":"瑞士信贷持仓"},"translate_title":"Illumina (ILMN) 启动新加坡基因组计划，覆盖 45 万居民","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AIPO":0.73,"AGIX":0.73,"QTOC":0.73,"VTHR":0.73,"BMED":0.63,"ARTY":0.73,"CHAT":0.73,"ILMN":1.5},"content_text":"Illumina (NasdaqGS: ILMN) has been selected for Phase III of Singapore's National Precision Medicine Programme, as announced for the SG-INSIGHT study. The company will provide whole-genome sequencing for approximately 450,000 residents, supporting large scale population genomics in Singapore. This engagement builds on earlier collaborations in the country and extends Illumina's operational and regulatory footprint across Asia. Illumina's role in the SG-INSIGHT whole-genome project is important, but investors should weigh it alongside other factors. We have also spotted 1 warning sign worth knowing about at Illumina.  For readers tracking how genomics and data science intersect in healthcare delivery, it may be worth exploring related opportunities in 33 healthcare AI stocks. NasdaqGS:ILMN Earnings & Revenue Growth as at Nov 2026 Illumina operates as a global life sciences supplier of sequencing and array technologies, so this Singapore precision medicine work taps directly into its core offering of whole genome tools. With a market value of about $35.7b and reach across multiple regions, the group already has a footprint that includes the broader Asia Pacific healthcare ecosystem. 3 things going right for Illumina that this headline doesn't cover. AdvertisementHow Illumina’s Singapore win stress-tests its clinical and data Narrative Illumina’s investment story leans on the idea that clinical sequencing and data-heavy products become a long-running, recurring engine, with AI tools and NovaSeq X capacity pulling through more consumables and software revenue. This Singapore precision medicine partnership plugs directly into that thesis because it is both a large clinical genomics project and a real-world data play.  \"The main requirement for this view is that Illumina maintains mid teens clinical consumables growth while scaling NovaSeq X placements and new data products sufficiently to offset ongoing weakness...\"  See how the full story points towards a $249 fair value for Illumina. The SG-INSIGHT award squarely supports the clinical-consumables catalyst in the Illumina Narrative. One in ten residents being sequenced creates a sizeable flow of whole-genome work that fits management’s focus on clinical routines rather than one-off research projects. It also helps the business anchor NovaSeq-class capacity in Asia, which matters when Thermo Fisher or Roche pursue the same hospital and public-health budgets. The same contract puts pressure on the Narrative’s data-and-AI leg. To justify the Story’s expectations, investors now need Illumina to convert this huge government cohort into BioInsight-style analytics, compliant under Singapore’s Healthcare Services Act, not just into sequencing throughput. If competitors win similar national projects and add richer software layers, this win may look more like table stakes than clear edge. The takeaway for you is that the Singapore news can either reinforce a clinical-sequencing bull case or underline execution risk on data and AI, depending on which Narrative you bring to it. One Illumina thread this article has not pulled yet Headline figures only tell part of Illumina’s story, and separate checks on the reliability of those reported profits raise a specific question that is worth answering before forming any firm view. See what our checks flag about the quality of Illumina's earnings. This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.52.1","shortVersion":"4.52.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2680705596","isCrawlerRequest":true}